{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T23:45:46Z","timestamp":1794527146018,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000320","name":"Alzheimer's Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Van Geest Foundation"},{"DOI":"10.13039\/501100000329","name":"Novo Nordisk UK Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-019-3259-x","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T09:03:02Z","timestamp":1554282182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":209,"title":["Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer\u2019s disease: study protocol for a randomised controlled trial (ELAD study)"],"prefix":"10.1186","volume":"20","author":[{"given":"Grazia Daniela","family":"Femminella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Frangou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon B.","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Busza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady","family":"McFarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Tadros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil H.","family":"Ridha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Bannister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Coulthard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben R.","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Prasanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Koranteng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehinde","family":"Junaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"McGuinness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Nilforooshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Macharouthu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Thacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naghma","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Mate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajeev","family":"Kshemendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Peter","family":"Passmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6551-2002","authenticated-orcid":false,"given":"Paul","family":"Edison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,3]]},"reference":[{"key":"3259_CR1","volume-title":"World Alzheimer Report 2015\u2014the global impact of dementia: an analysis of prevalence, incidence, cost and trends","author":"M Prince","year":"2015","unstructured":"Prince M, Wimo A, Guerchet M, Ali G, Wu Y, Prina M: World Alzheimer Report 2015\u2014the global impact of dementia: an analysis of prevalence, incidence, cost and trends. 2015. Google Scholar 2017."},{"issue":"4","key":"3259_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/alzrt269","volume":"6","author":"JL Cummings","year":"2014","unstructured":"Cummings JL, Morstorf T, Zhong K. Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6(4):37.","journal-title":"Alzheimers Res Ther"},{"key":"3259_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejphar.2016.04.052","volume":"783","author":"L Qi","year":"2016","unstructured":"Qi L, Ke L, Liu X, Liao L, Ke S, Liu X, Wang Y, Lin X, Zhou Y, Wu L, et al. Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3beta pathway in an amyloid beta protein induced alzheimer disease mouse model. Eur J Pharmacol. 2016;783:23\u201332.","journal-title":"Eur J Pharmacol"},{"key":"3259_CR4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","volume":"8","author":"M Gejl","year":"2016","unstructured":"Gejl M, Gjedde A, Egefjord L, Moller A, Hansen SB, Vang K, Rodell A, Braendgaard H, Gottrup H, Schacht A, et al. In Alzheimer\u2019s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci. 2016;8:108.","journal-title":"Front Aging Neurosci"},{"issue":"22","key":"3259_CR5","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1212\/WNL.0b013e3181ffe4f6","volume":"75","author":"EM Schrijvers","year":"2010","unstructured":"Schrijvers EM, Witteman JC, Sijbrands EJ, Hofman A, Koudstaal PJ, Breteler MM. Insulin metabolism and the risk of Alzheimer disease: the Rotterdam study. Neurology. 2010;75(22):1982\u20137.","journal-title":"Neurology"},{"issue":"2","key":"3259_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.neurobiolaging.2008.04.002","volume":"31","author":"AM Moloney","year":"2010","unstructured":"Moloney AM, Griffin RJ, Timmons S, O\u2019Connor R, Ravid R, O\u2019Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1\/2 in Alzheimer\u2019s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging. 2010;31(2):224\u201343.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"3259_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0031-9384(04)00348-8","volume":"83","author":"U Stockhorst","year":"2004","unstructured":"Stockhorst U, de Fries D, Steingrueber HJ, Scherbaum WA. Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans. Physiol Behav. 2004;83(1):47\u201354.","journal-title":"Physiol Behav"},{"issue":"3","key":"3259_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1515\/REVNEURO.2005.16.3.181","volume":"16","author":"C Holscher","year":"2005","unstructured":"Holscher C. Development of beta-amyloid-induced neurodegeneration in Alzheimer\u2019s disease and novel neuroprotective strategies. Rev Neurosci. 2005;16(3):181\u2013212.","journal-title":"Rev Neurosci"},{"issue":"1\u20133","key":"3259_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejphar.2004.02.049","volume":"490","author":"S Hoyer","year":"2004","unstructured":"Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol. 2004;490(1\u20133):115\u201325.","journal-title":"Eur J Pharmacol"},{"key":"3259_CR10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.brainresrev.2007.09.001","volume":"56","author":"L Li","year":"2007","unstructured":"Li L, H\u00f6lscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev. 2007;56:384\u2013402.","journal-title":"Brain Res Rev"},{"issue":"9","key":"3259_CR11","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1111\/j.1530-0277.2007.00450.x","volume":"31","author":"AC Cohen","year":"2007","unstructured":"Cohen AC, Tong M, Wands JR, de la Monte SM. Insulin and insulin-like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model. Alcohol Clin Exp Res. 2007;31(9):1558\u201373.","journal-title":"Alcohol Clin Exp Res"},{"issue":"1\u20133","key":"3259_CR12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2004.02.047","volume":"490","author":"P van Dam","year":"2004","unstructured":"van Dam P, Aleman A. Insulin-like growth factor-I, cognition and brain aging. Eur J Pharmacol. 2004;490(1\u20133):87\u201395.","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"3259_CR13","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.2337\/db07-0171","volume":"56","author":"ZG Li","year":"2007","unstructured":"Li ZG, Zhang W, Sima AA. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes. 2007;56(7):1817\u201324.","journal-title":"Diabetes"},{"issue":"1\u20133","key":"3259_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejphar.2004.02.050","volume":"490","author":"E Carro","year":"2004","unstructured":"Carro E, Torres AI. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer\u2019s disease. Eur J Pharmacol. 2004;490(1\u20133):127\u201333.","journal-title":"Eur J Pharmacol"},{"issue":"1\u20133","key":"3259_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ejphar.2004.02.048","volume":"490","author":"GS Watson","year":"2004","unstructured":"Watson GS, Craft S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer\u2019s disease. Eur J Pharmacol. 2004;490(1\u20133):97\u2013113.","journal-title":"Eur J Pharmacol"},{"issue":"490","key":"3259_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejphar.2004.02.045","volume":"490","author":"WQ Zhao","year":"2004","unstructured":"Zhao WQ, Chen H, Quon MJ, Alkon DL. Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol. 2004;490(490):71\u201381.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"3259_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JAD-2008-13309","volume":"13","author":"MA Reger","year":"2008","unstructured":"Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH 2nd, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis. 2008;13(3):323\u201331.","journal-title":"J Alzheimers Dis"},{"key":"3259_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/gps.2089","volume":"24","author":"OI Okereke","year":"2008","unstructured":"Okereke OI, Selkoe DJ, Pollak MN, Stampfer MJ, Hu FB, Hankinson SE, Grodstein F. A profile of impaired insulin degradation in relation to late-life cognitive decline: a preliminary investigation. Int J Geriatr Psychiatry. 2008;24:177\u201382.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"3259_CR19","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1212\/01.WNL.0000265401.62434.36","volume":"70","author":"MA Reger","year":"2008","unstructured":"Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008;70(6):440\u20138.","journal-title":"Neurology"},{"issue":"1","key":"3259_CR20","first-page":"51","volume":"68","author":"LD Baker","year":"2010","unstructured":"Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol. 2010;68(1):51\u20137.","journal-title":"Arch Neurol"},{"issue":"10","key":"3259_CR21","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1111\/dom.13373","volume":"20","author":"B Cao","year":"2018","unstructured":"Cao B, Rosenblat JD, Brietzke E, Park C, Lee Y, Musial N, Pan Z, Mansur RB, McIntyre RS. Comparative efficacy and acceptability of antidiabetic agents for Alzheimer\u2019s disease and mild cognitive impairment: a systematic review and network meta-analysis. Diabetes Obes Metab. 2018;20(10):2467\u201371.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 3","key":"3259_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1463-1326.2009.01075.x","volume":"11","author":"L Blonde","year":"2009","unstructured":"Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab. 2009;11(Suppl 3):26\u201334.","journal-title":"Diabetes Obes Metab"},{"key":"3259_CR23","doi-asserted-by":"publisher","unstructured":"Gilbert MP, Bain SC, Franek E, Jodar-Gimeno E, Nauck MA, Pratley R, Rea RR, Kerr Saraiva JF, Rasmussen S, Tornoe K, et al. Effect of liraglutide on cardiovascular outcomes in elderly patients: a post hoc analysis of a randomized controlled trial. Ann Intern Med. 2018;169. \n                    https:\/\/doi.org\/10.7326\/M18-1569\n                    \n                  .","DOI":"10.7326\/M18-1569"},{"issue":"3","key":"3259_CR24","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/dom.12012","volume":"15","author":"M Nauck","year":"2013","unstructured":"Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, Tankova T, Mitha I, Matthews DR. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab. 2013;15(3):204\u201312.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"3259_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/MED.0b013e32825ea2ba","volume":"14","author":"JP Frias","year":"2007","unstructured":"Frias JP, Edelman SV. Incretins and their role in the management of diabetes. Curr Opin Endocrinol Diabetes Obes. 2007;14(4):269\u201376.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"2","key":"3259_CR26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.abb.2004.05.005","volume":"428","author":"BD Green","year":"2004","unstructured":"Green BD, Gault VA, Flatt PR, Harriott P, Greer B, O\u2019Harte FP. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8\/Ala2 with 2-aminobutyric acid. Arch Biochem Biophys. 2004;428(2):136\u201343.","journal-title":"Arch Biochem Biophys"},{"issue":"3","key":"3259_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2174\/1567205054367892","volume":"2","author":"T Perry","year":"2005","unstructured":"Perry T, Greig NH. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer\u2019s disease. Curr Alzheimer Res. 2005;2(3):377\u201385.","journal-title":"Curr Alzheimer Res"},{"issue":"11","key":"3259_CR28","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1111\/j.1460-9568.1995.tb00650.x","volume":"7","author":"R Goke","year":"1995","unstructured":"Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci. 1995;7(11):2294\u2013300.","journal-title":"Eur J Neurosci"},{"key":"3259_CR29","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/WNR.0b013e32832fbf14","volume":"20","author":"A Hamilton","year":"2009","unstructured":"Hamilton A, Holscher C. Receptors for the insulin-like peptide GLP-1 are expressed on neurons in the CNS. Neuroreport. 2009;20:1161\u20136.","journal-title":"Neuroreport"},{"issue":"12","key":"3259_CR30","doi-asserted-by":"publisher","first-page":"4600","DOI":"10.1210\/endo.141.12.7806","volume":"141","author":"R Perfetti","year":"2000","unstructured":"Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology. 2000;141(12):4600\u20135.","journal-title":"Endocrinology"},{"issue":"3","key":"3259_CR31","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1124\/jpet.300.3.958","volume":"300","author":"T Perry","year":"2002","unstructured":"Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM, Greig NH. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther. 2002;300(3):958\u201366.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"3259_CR32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/jnr.10611","volume":"72","author":"T Perry","year":"2003","unstructured":"Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res. 2003;72(5):603\u201312.","journal-title":"J Neurosci Res"},{"issue":"9","key":"3259_CR33","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/nm919","volume":"9","author":"MJ During","year":"2003","unstructured":"During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9(9):1173\u20139.","journal-title":"Nat Med"},{"key":"3259_CR34","unstructured":"McClean P, Pathasarthy V, Gault V, Holscher C. Liraglutide, a novel GLP-1 analogue, prevents the impairment of learning and LTP in an APP\/PS-1 mouse model of Alzheimer\u2019s disease. In: Society for Neuroscience: 2010. San Diego; 2010. p. K20."},{"key":"3259_CR35","doi-asserted-by":"publisher","unstructured":"Gengler S, McClean P, McCurtin R, Gault V, Holscher C. Val (8) GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP\/PS1 mice. Neurobiol Aging. 2012;33(2):265-76. \n                    https:\/\/doi.org\/10.1016\/j.neurobiolaging.2010.1002.1014\n                    \n                  .","DOI":"10.1016\/j.neurobiolaging.2010.1002.1014"},{"issue":"46","key":"3259_CR36","doi-asserted-by":"publisher","first-page":"33305","DOI":"10.1074\/jbc.M610390200","volume":"282","author":"M Townsend","year":"2007","unstructured":"Townsend M, Mehta T, Selkoe DJ. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem. 2007;282(46):33305\u201312.","journal-title":"J Biol Chem"},{"issue":"4","key":"3259_CR37","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/jnr.22565","volume":"89","author":"A Hamilton","year":"2011","unstructured":"Hamilton A, Patterson S, Porter D, Gault VA, Holscher C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res. 2011;89(4):481\u20139.","journal-title":"J Neurosci Res"},{"key":"3259_CR38","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","volume":"31","author":"P McClean","year":"2011","unstructured":"McClean P, Parthsarathy V, Faivre E, H\u00f6lscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease. J Neurosci. 2011;31:6587\u201394.","journal-title":"J Neurosci"},{"issue":"4","key":"3259_CR39","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1172\/JCI59903","volume":"122","author":"K Talbot","year":"2012","unstructured":"Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, et al. Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316\u201338.","journal-title":"J Clin Invest"},{"issue":"10","key":"3259_CR40","first-page":"1410","volume":"45","author":"A Vella","year":"2002","unstructured":"Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia. 2002;45(10):1410\u20135.","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"3259_CR41","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1017\/S0317167100005552","volume":"34","author":"A Kirk","year":"2007","unstructured":"Kirk A. Target symptoms and outcome measures: cognition. Can J Neurol Sci. 2007;34(Suppl 1):S42\u20136.","journal-title":"Can J Neurol Sci"},{"issue":"1 Suppl","key":"3259_CR42","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jalz.2011.11.002","volume":"9","author":"JM Cedarbaum","year":"2013","unstructured":"Cedarbaum JM, Jaros M, Hernandez C, Coley N, Andrieu S, Grundman M, Vellas B, Alzheimer\u2019s Disease Neuroimaging Initiative. Rationale for use of the clinical dementia rating sum of boxes as a primary outcome measure for Alzheimer\u2019s disease clinical trials. Alzheimers Dement. 2013;9(1 Suppl):S45\u201355.","journal-title":"Alzheimers Dement"},{"issue":"Suppl 2","key":"3259_CR43","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","volume":"11","author":"D Galasko","year":"1997","unstructured":"Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S. An inventory to assess activities of daily living for clinical trials in Alzheimer\u2019s disease. The Alzheimer\u2019s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S33\u20139.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"6","key":"3259_CR44","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s40262-015-0343-6","volume":"55","author":"LV Jacobsen","year":"2016","unstructured":"Jacobsen LV, Flint A, Olsen AK, Ingwersen SH. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2016;55(6):657\u201372.","journal-title":"Clin Pharmacokinet"},{"key":"3259_CR45","doi-asserted-by":"crossref","unstructured":"Peterson GE, Pollom RD. Liraglutide in clinical practice: dosing, safety and efficacy. Int J Clin Pract Suppl. 2010;(167):35\u201343.","DOI":"10.1111\/j.1742-1241.2010.02498.x"},{"issue":"7","key":"3259_CR46","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","volume":"32","author":"SM Landau","year":"2011","unstructured":"Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32(7):1207\u201318.","journal-title":"Neurobiol Aging"},{"key":"3259_CR47","volume-title":"Pharmaceutical distributor, wholesale, healthcare","author":"Mawdsleys","year":"2017","unstructured":"Mawdsleys: Pharmaceutical distributor, wholesale, healthcare. 2017."},{"key":"3259_CR48","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.","journal-title":"BMJ"},{"issue":"4","key":"3259_CR49","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"3259_CR50","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, et al. Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734\u201346.","journal-title":"Lancet Neurol"}],"updated-by":[{"DOI":"10.1186\/s13063-020-04608-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,7,19]],"date-time":"2020-07-19T00:00:00Z","timestamp":1595116800000}}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3259-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3259-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3259-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,19]],"date-time":"2020-07-19T09:03:50Z","timestamp":1595149430000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3259-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,3]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3259"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3259-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,3]]},"assertion":[{"value":"23 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via the original article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the local and regional regulatory ethics committees (London Riverside Research Ethics Committee \u2013 study reference number 13\/LO\/0699, and Health Research Authority, UK), and the Medicines and Healthcare products Regulatory Agency (MHRA \u2013 EudraCT number 2013\u2013000962-13). Approval for administration of radioactivity was given by the Administration of Radioactive Substances Advisory Committee (ARSAC).All participants and study partners signed an Informed Consent Form prior to entry into the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr Edison was funded by the Medical Research Council and now by the Higher Education Funding Council for England (HEFCE). He has also received grants from Alzheimer\u2019s Research, UK, Alzheimer\u2019s Drug Discovery Foundation, Alzheimer\u2019s Society, UK, Novo Nordisk, GE Healthcare, Astra Zeneca, Pfizer, Eli Lilly and Piramal Life Sciences. The other authors have nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"191"}}